IceCure Medical (ICCM) Projected to Post Quarterly Earnings on Wednesday

IceCure Medical (NASDAQ:ICCM) is anticipated to post its Q3 2025 results before the market opens on Wednesday, November 19th. Analysts expect IceCure Medical to post earnings of ($0.06) per share and revenue of $0.6260 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 10:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Wednesday, August 13th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.12. IceCure Medical had a negative net margin of 317.62% and a negative return on equity of 136.96%. The firm had revenue of $0.66 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IceCure Medical Stock Up 0.3%

Shares of ICCM traded up $0.00 on Thursday, reaching $0.71. The company’s stock had a trading volume of 370,577 shares, compared to its average volume of 929,997. IceCure Medical has a twelve month low of $0.56 and a twelve month high of $1.66. The stock has a market capitalization of $48.78 million, a PE ratio of -4.44 and a beta of 0.28. The company has a current ratio of 1.18, a quick ratio of 0.88 and a debt-to-equity ratio of 0.02. The firm has a fifty day moving average of $0.90 and a 200-day moving average of $0.97.

Analyst Ratings Changes

Several brokerages have recently commented on ICCM. HC Wainwright increased their price objective on IceCure Medical from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Brookline Capital Management reiterated a “buy” rating on shares of IceCure Medical in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of IceCure Medical in a research note on Wednesday, October 8th. Loop Capital set a $2.77 price objective on shares of IceCure Medical in a report on Wednesday, August 13th. Finally, Zacks Research lowered shares of IceCure Medical from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 15th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, IceCure Medical presently has a consensus rating of “Hold” and a consensus target price of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.